Published in Onco Targets Ther on February 18, 2009
Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions. ISRN Gastroenterol (2012) 1.56
Induction of innate lymphoid cell-derived interleukin-22 by the transcription factor STAT3 mediates protection against intestinal infection. Immunity (2014) 1.14
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. Ann Oncol (2014) 0.83
Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials. Onco Targets Ther (2014) 0.80
Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. Biomed Chromatogr (2012) 0.79
Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma. Int J Mol Sci (2017) 0.76
Oral administration of sunitinib malate for long-term survival of a patient with multiple lung metastases from renal leiomyosarcoma. Onco Targets Ther (2016) 0.75
Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma. Arch Med Sci (2016) 0.75
Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer. Onco Targets Ther (2015) 0.75
The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. Ther Adv Med Oncol (2013) 0.75
Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib. Eur Radiol (2014) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95
Renal-cell carcinoma. N Engl J Med (1996) 11.46
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9.92
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Sunitinib: from rational design to clinical efficacy. J Clin Oncol (2007) 7.26
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (2007) 6.76
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2007) 5.10
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2008) 4.50
Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol (2005) 2.05
Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid (2007) 2.03
Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol (2007) 1.87
Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol (2004) 1.86
Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol (2005) 1.85
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer (2008) 1.69
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol (2008) 1.63
Pharmacogenetics of oral anticoagulants. Pharmacogenetics (2003) 1.54
Epidemiologic aspects of renal cell carcinoma. Semin Oncol (2006) 1.50
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med (2008) 1.47
Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol (2007) 1.45
Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol (2006) 1.42
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer (2008) 1.41
Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens (2002) 1.38
Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer (2008) 1.34
Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction. Int J Cardiol (2005) 0.97
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer (2008) 0.97
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer (2008) 0.92
Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet (2007) 0.83
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res (2009) 5.10
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2007) 5.10
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res (2008) 2.84
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61
Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol (2011) 2.13
Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. Oncology (Williston Park) (2011) 2.06
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol (2008) 2.03
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer (2009) 2.02
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol (2008) 2.00
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol (2011) 1.92
Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res (2010) 1.92
Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidence. Am J Surg Pathol (2009) 1.84
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer (2010) 1.77
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol (2007) 1.66
The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol (2012) 1.65
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res (2013) 1.62
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res (2006) 1.60
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. J Natl Cancer Inst (2014) 1.56
Appetite and cancer-associated anorexia: a review. J Clin Oncol (2004) 1.56
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol (2011) 1.51
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol (2011) 1.33
A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res (2011) 1.27
Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol (2007) 1.26
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol (2010) 1.23
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol (2010) 1.22
A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res (2009) 1.19
Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol (2006) 1.18
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.13
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol (2005) 1.12
Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer (2007) 1.09
Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist (2009) 1.08
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer (2006) 1.05
Brain metastases from bladder carcinoma: presentation, treatment and survival. J Urol (2002) 1.02
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer (2006) 1.02
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer (2010) 1.02
Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol (2009) 1.01
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs (2007) 1.01
HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am J Clin Pathol (2008) 1.00
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res (2010) 0.98
HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Mod Pathol (2011) 0.98
Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma. Cancer (2012) 0.97
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol (2012) 0.97
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer (2008) 0.97
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol (2014) 0.96
GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosis. Cancer Res (2008) 0.96
A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol (2008) 0.95
Pazopanib for the treatment of renal cancer. Expert Opin Pharmacother (2011) 0.95
Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer (2007) 0.95
Molecular biomarkers in advanced renal cell carcinoma. Clin Cancer Res (2014) 0.95
Germline and somatic DNA methylation and epigenetic regulation of KILLIN in renal cell carcinoma. Genes Chromosomes Cancer (2011) 0.94
Noncytotoxic differentiation treatment of renal cell cancer. Cancer Res (2011) 0.94
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer (2013) 0.94
Differential expression of caveolin-1 in renal neoplasms. Cancer (2007) 0.93
The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. Cancer (2010) 0.92
Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. Trends Mol Med (2010) 0.91
Phase I trial of pomalidomide given for patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.90
Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res (2008) 0.88
Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol (2009) 0.87
Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome. Cancer (2011) 0.86
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Invest New Drugs (2010) 0.86
The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis. Semin Oncol (2007) 0.84
Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects. Clin Cancer Res (2003) 0.83
Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Invest New Drugs (2010) 0.83
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs (2009) 0.83
Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Prostate Cancer (2004) 0.83
Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol (2011) 0.83
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer (2008) 0.83
The future of drug development in urothelial cancer. J Clin Oncol (2011) 0.82
Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity. Urol Oncol (2007) 0.81
Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial. Cancer (2010) 0.81
Hormonal therapy for prostate cancer: primum non nocere. Urology (2002) 0.81
Renal cell carcinoma: ten years of significant advances. Target Oncol (2010) 0.81
Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group. Invest New Drugs (2002) 0.80
A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. Invest New Drugs (2013) 0.80
Second-line chemotherapy for advanced urothelial cancer: because we should or because we can? J Clin Oncol (2009) 0.80
Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma. BJU Int (2011) 0.80
Paracolic recurrence of stage I seminoma. Urology (2003) 0.80
Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies. Nat Clin Pract Urol (2005) 0.80
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma. J Cancer Surviv (2011) 0.80
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer (2006) 0.79
Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder. BJU Int (2007) 0.79